nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—HIPK4—brain—meningioma	0.0111	0.0293	CbGeAlD
Erlotinib—LTK—brain—meningioma	0.011	0.0289	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—meningioma	0.0109	0.0287	CbGeAlD
Erlotinib—JAK3—cerebellum—meningioma	0.0108	0.0285	CbGeAlD
Erlotinib—ULK3—medulla oblongata—meningioma	0.0104	0.0274	CbGeAlD
Erlotinib—MAP2K5—brainstem—meningioma	0.0103	0.0272	CbGeAlD
Erlotinib—TNK1—cerebellum—meningioma	0.0099	0.0261	CbGeAlD
Erlotinib—MKNK1—medulla oblongata—meningioma	0.00976	0.0258	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—meningioma	0.00969	0.0256	CbGeAlD
Erlotinib—AURKC—brain—meningioma	0.00945	0.025	CbGeAlD
Erlotinib—ULK3—spinal cord—meningioma	0.00925	0.0244	CbGeAlD
Erlotinib—SLK—medulla oblongata—meningioma	0.00924	0.0244	CbGeAlD
Erlotinib—EPHA6—brain—meningioma	0.00875	0.0231	CbGeAlD
Erlotinib—JAK3—brain—meningioma	0.00875	0.0231	CbGeAlD
Erlotinib—MKNK1—spinal cord—meningioma	0.0087	0.023	CbGeAlD
Erlotinib—FLT3—cerebellum—meningioma	0.0085	0.0225	CbGeAlD
Erlotinib—SLK—spinal cord—meningioma	0.00824	0.0218	CbGeAlD
Erlotinib—ABL2—cerebellum—meningioma	0.00812	0.0214	CbGeAlD
Erlotinib—TNK1—brain—meningioma	0.00804	0.0212	CbGeAlD
Erlotinib—MAP3K19—brain—meningioma	0.00796	0.021	CbGeAlD
Erlotinib—ABL1—brainstem—meningioma	0.00794	0.021	CbGeAlD
Erlotinib—EGFR—cerebellum—meningioma	0.00792	0.0209	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—meningioma	0.00768	0.0203	CbGeAlD
Erlotinib—ULK3—cerebellum—meningioma	0.00733	0.0194	CbGeAlD
Erlotinib—MAP2K5—medulla oblongata—meningioma	0.00718	0.019	CbGeAlD
Erlotinib—MKNK1—cerebellum—meningioma	0.0069	0.0182	CbGeAlD
Erlotinib—ABL2—brain—meningioma	0.00659	0.0174	CbGeAlD
Erlotinib—SLK—cerebellum—meningioma	0.00654	0.0173	CbGeAlD
Erlotinib—EGFR—brain—meningioma	0.00644	0.017	CbGeAlD
Erlotinib—MAP2K5—spinal cord—meningioma	0.0064	0.0169	CbGeAlD
Erlotinib—PIP4K2C—brain—meningioma	0.00624	0.0165	CbGeAlD
Erlotinib—ULK3—brain—meningioma	0.00596	0.0157	CbGeAlD
Erlotinib—STK10—cerebellum—meningioma	0.00568	0.015	CbGeAlD
Erlotinib—MKNK1—brain—meningioma	0.00561	0.0148	CbGeAlD
Erlotinib—SLCO2B1—medulla oblongata—meningioma	0.00559	0.0148	CbGeAlD
Erlotinib—ABL1—medulla oblongata—meningioma	0.00554	0.0146	CbGeAlD
Erlotinib—SLK—brain—meningioma	0.00531	0.014	CbGeAlD
Erlotinib—ORM1—spinal cord—meningioma	0.0052	0.0137	CbGeAlD
Erlotinib—MAP2K5—cerebellum—meningioma	0.00508	0.0134	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—meningioma	0.00498	0.0132	CbGeAlD
Erlotinib—ABL1—spinal cord—meningioma	0.00494	0.013	CbGeAlD
Erlotinib—STK10—brain—meningioma	0.00462	0.0122	CbGeAlD
Erlotinib—MAP2K5—brain—meningioma	0.00412	0.0109	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—meningioma	0.00395	0.0104	CbGeAlD
Erlotinib—ABL1—cerebellum—meningioma	0.00392	0.0103	CbGeAlD
Erlotinib—ABCG2—medulla oblongata—meningioma	0.00349	0.00922	CbGeAlD
Erlotinib—CYP2D6—brainstem—meningioma	0.00343	0.00907	CbGeAlD
Erlotinib—CYP1B1—cerebellum—meningioma	0.00332	0.00876	CbGeAlD
Erlotinib—SLCO2B1—brain—meningioma	0.00321	0.00847	CbGeAlD
Erlotinib—ABL1—brain—meningioma	0.00318	0.0084	CbGeAlD
Erlotinib—ABCG2—spinal cord—meningioma	0.00311	0.00823	CbGeAlD
Erlotinib—ALB—brain—meningioma	0.00294	0.00775	CbGeAlD
Erlotinib—CYP1B1—brain—meningioma	0.00269	0.00711	CbGeAlD
Erlotinib—ABCG2—cerebellum—meningioma	0.00247	0.00652	CbGeAlD
Erlotinib—CYP2C8—brain—meningioma	0.00206	0.00545	CbGeAlD
Erlotinib—ABCG2—brain—meningioma	0.00201	0.0053	CbGeAlD
Erlotinib—CYP1A1—brain—meningioma	0.0019	0.00503	CbGeAlD
Erlotinib—ABCB1—medulla oblongata—meningioma	0.00172	0.00455	CbGeAlD
Erlotinib—CYP2D6—cerebellum—meningioma	0.00169	0.00447	CbGeAlD
Erlotinib—ABCB1—spinal cord—meningioma	0.00154	0.00406	CbGeAlD
Erlotinib—CYP2D6—brain—meningioma	0.00137	0.00363	CbGeAlD
Erlotinib—ABCB1—cerebellum—meningioma	0.00122	0.00322	CbGeAlD
Erlotinib—ABCB1—brain—meningioma	0.000989	0.00261	CbGeAlD
Erlotinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—AKT1—meningioma	0.000908	0.00146	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—ERBB2—meningioma	0.000907	0.00146	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—ERBB2—meningioma	0.000903	0.00145	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—TP53—meningioma	0.000899	0.00145	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Telomerase—AKT1—meningioma	0.000897	0.00144	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00089	0.00143	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TSHB—meningioma	0.000889	0.00143	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PLAUR—meningioma	0.000885	0.00142	CbGpPWpGaD
Erlotinib—EGFR—Disease—AP1B1—meningioma	0.000884	0.00142	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—PTEN—meningioma	0.000873	0.00141	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—PTEN—meningioma	0.000869	0.0014	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—PDGFB—meningioma	0.000863	0.00139	CbGpPWpGaD
Erlotinib—ABCG2—HIF-1-alpha transcription factor network—AKT1—meningioma	0.000858	0.00138	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—meningioma	0.000852	0.00137	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—ERBB2—meningioma	0.000849	0.00137	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—ERBB2—meningioma	0.000849	0.00137	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.000849	0.00137	CbGpPWpGaD
Erlotinib—MAP2K5—Insulin Signaling—AKT1—meningioma	0.000843	0.00136	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—ERBB2—meningioma	0.000842	0.00135	CbGpPWpGaD
Erlotinib—MAP2K5—EGF/EGFR Signaling Pathway—AKT1—meningioma	0.000835	0.00134	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—ERBB2—meningioma	0.000834	0.00134	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—PTEN—meningioma	0.000831	0.00134	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—ERBB2—meningioma	0.00083	0.00134	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—PTEN—meningioma	0.000822	0.00132	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—PTEN—meningioma	0.000818	0.00132	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—AKT1—meningioma	0.000811	0.0013	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PDGFB—meningioma	0.000802	0.00129	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—ERBB2—meningioma	0.000802	0.00129	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.000799	0.00129	CbGpPWpGaD
Erlotinib—JAK3—Platelet activation, signaling and aggregation—AKT1—meningioma	0.000799	0.00129	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.000797	0.00128	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ALAD—meningioma	0.000794	0.00128	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—ERBB2—meningioma	0.000786	0.00126	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—PTEN—meningioma	0.000781	0.00126	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—PTEN—meningioma	0.000777	0.00125	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—PTEN—meningioma	0.000777	0.00125	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—PTEN—meningioma	0.000773	0.00124	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—AKT1—meningioma	0.000772	0.00124	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—PTEN—meningioma	0.00077	0.00124	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HES1—meningioma	0.000763	0.00123	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.000759	0.00122	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD34—meningioma	0.000757	0.00122	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SMO—meningioma	0.000756	0.00122	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.000752	0.00121	CbGpPWpGaD
Erlotinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.000743	0.0012	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALAD—meningioma	0.000741	0.00119	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—AKT1—meningioma	0.000735	0.00118	CbGpPWpGaD
Erlotinib—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—meningioma	0.000732	0.00118	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PGR—meningioma	0.000725	0.00117	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TSHB—meningioma	0.000725	0.00117	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.000724	0.00117	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—PTEN—meningioma	0.000724	0.00117	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—PTEN—meningioma	0.000724	0.00117	CbGpPWpGaD
Erlotinib—EGFR—Androgen receptor signaling pathway—AKT1—meningioma	0.000723	0.00116	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTSL—meningioma	0.000722	0.00116	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—AKT1—meningioma	0.00072	0.00116	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—PTEN—meningioma	0.000718	0.00115	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—meningioma	0.000714	0.00115	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—PTEN—meningioma	0.000711	0.00114	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—PTEN—meningioma	0.000708	0.00114	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.000689	0.00111	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—PTEN—meningioma	0.000684	0.0011	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—meningioma	0.000683	0.0011	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.000681	0.0011	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALAD—meningioma	0.000674	0.00108	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—PTEN—meningioma	0.00067	0.00108	CbGpPWpGaD
Erlotinib—EGFR—PI-3K cascade—AKT1—meningioma	0.00067	0.00108	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TSHB—meningioma	0.000658	0.00106	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HES1—meningioma	0.000657	0.00106	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—meningioma	0.000657	0.00106	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PDGFB—meningioma	0.000655	0.00105	CbGpPWpGaD
Erlotinib—EGFR—PI3K/AKT activation—AKT1—meningioma	0.000654	0.00105	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HES1—meningioma	0.000652	0.00105	CbGpPWpGaD
Erlotinib—EGFR—GAB1 signalosome—AKT1—meningioma	0.000649	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD34—meningioma	0.000647	0.00104	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.000641	0.00103	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PDGFB—meningioma	0.00064	0.00103	CbGpPWpGaD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.000634	0.00102	CbGpPWpGaD
Erlotinib—EGFR—ErbB1 downstream signaling—AKT1—meningioma	0.000634	0.00102	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—meningioma	0.000627	0.00101	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PLAU—meningioma	0.000621	0.000999	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTSL—meningioma	0.000617	0.000993	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SMO—meningioma	0.000616	0.000992	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—ERBB2—meningioma	0.000613	0.000986	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—PDGFB—meningioma	0.000611	0.000983	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—AKT1—meningioma	0.000608	0.000979	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—meningioma	0.000596	0.000959	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PGR—meningioma	0.000591	0.000951	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—ERBB2—meningioma	0.000578	0.000931	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PDGFB—meningioma	0.000576	0.000927	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PDGFB—meningioma	0.000562	0.000904	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—meningioma	0.000561	0.000903	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—SMO—meningioma	0.00056	0.000901	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—AKT1—meningioma	0.000555	0.000892	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.000544	0.000876	CbGpPWpGaD
Erlotinib—MKNK1—Disease—ERBB2—meningioma	0.000538	0.000865	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—AKT1—meningioma	0.00053	0.000852	CbGpPWpGaD
Erlotinib—EGFR—Disease—CST3—meningioma	0.000526	0.000846	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—AKT1—meningioma	0.000524	0.000844	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—ERBB2—meningioma	0.000523	0.000842	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—meningioma	0.000515	0.000829	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—AKT1—meningioma	0.000513	0.000826	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TSHB—meningioma	0.000512	0.000823	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—AKT1—meningioma	0.000501	0.000806	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HES1—meningioma	0.000495	0.000797	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—PTEN—meningioma	0.000493	0.000794	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PDGFB—meningioma	0.000492	0.000792	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—meningioma	0.000488	0.000785	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALAD—meningioma	0.000483	0.000777	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—AKT1—meningioma	0.000479	0.000771	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TSHB—meningioma	0.000477	0.000768	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—AKT1—meningioma	0.000474	0.000763	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PDGFB—meningioma	0.000473	0.000761	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—AKT1—meningioma	0.000471	0.000759	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.000465	0.000748	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—meningioma	0.000464	0.000746	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.000459	0.000739	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTEN—meningioma	0.000459	0.000738	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALAD—meningioma	0.000456	0.000734	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—AKT1—meningioma	0.00045	0.000724	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—AKT1—meningioma	0.000448	0.000721	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—AKT1—meningioma	0.000448	0.000721	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—AKT1—meningioma	0.000446	0.000717	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—AKT1—meningioma	0.000444	0.000714	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ERBB2—meningioma	0.000439	0.000707	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.000437	0.000704	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—ERBB2—meningioma	0.000437	0.000704	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PLAUR—meningioma	0.000436	0.000701	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—AKT1—meningioma	0.000435	0.0007	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TSHB—meningioma	0.000434	0.000699	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PDGFB—meningioma	0.000424	0.000682	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALAD—meningioma	0.000418	0.000673	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—AKT1—meningioma	0.000417	0.000672	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—AKT1—meningioma	0.000417	0.000672	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.000417	0.000672	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ALAD—meningioma	0.000416	0.000669	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—AKT1—meningioma	0.000414	0.000666	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—AKT1—meningioma	0.000412	0.000663	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—AKT1—meningioma	0.00041	0.00066	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—AKT1—meningioma	0.000408	0.000657	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HES1—meningioma	0.000404	0.00065	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.000403	0.000649	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—AKT1—meningioma	0.000394	0.000635	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.000393	0.000632	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSHB—meningioma	0.000389	0.000626	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—AKT1—meningioma	0.000386	0.000621	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ERBB2—meningioma	0.000386	0.000621	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ERBB2—meningioma	0.000377	0.000606	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PTEN—meningioma	0.000375	0.000603	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—ERBB2—meningioma	0.000374	0.000601	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.00037	0.000595	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALAD—meningioma	0.000364	0.000586	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PDGFB—meningioma	0.000345	0.000556	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.000344	0.000553	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALAD—meningioma	0.000343	0.000552	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PDGFB—meningioma	0.000335	0.00054	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMO—meningioma	0.000331	0.000532	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB2—meningioma	0.00033	0.000531	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PTEN—meningioma	0.000329	0.00053	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PTEN—meningioma	0.000321	0.000517	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PGR—meningioma	0.000317	0.00051	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB2—meningioma	0.000317	0.00051	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PDGFB—meningioma	0.000315	0.000507	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TSHB—meningioma	0.000311	0.000501	CbGpPWpGaD
Erlotinib—EGFR—Disease—HES1—meningioma	0.000309	0.000498	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PLAU—meningioma	0.000306	0.000492	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TSHB—meningioma	0.000294	0.000473	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000292	0.00047	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALAD—meningioma	0.000291	0.000468	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PDGFB—meningioma	0.000287	0.000461	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—AKT1—meningioma	0.000284	0.000457	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB2—meningioma	0.000284	0.000457	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PTEN—meningioma	0.000281	0.000453	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PTEN—meningioma	0.00027	0.000435	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TSHB—meningioma	0.000269	0.000434	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TSHB—meningioma	0.000268	0.000431	CbGpPWpGaD
Erlotinib—EGFR—Disease—PDGFB—meningioma	0.000265	0.000426	CbGpPWpGaD
Erlotinib—MKNK1—Disease—AKT1—meningioma	0.000264	0.000425	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AKT1—meningioma	0.00026	0.000419	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AKT1—meningioma	0.000252	0.000406	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—meningioma	0.00025	0.000402	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTEN—meningioma	0.000242	0.00039	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AKT1—meningioma	0.000236	0.00038	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TSHB—meningioma	0.000235	0.000378	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.000235	0.000378	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB2—meningioma	0.000232	0.000373	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB2—meningioma	0.000225	0.000362	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALAD—meningioma	0.000224	0.000361	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TSHB—meningioma	0.000221	0.000356	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—meningioma	0.000219	0.000353	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HES1—meningioma	0.000217	0.000349	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—meningioma	0.000216	0.000347	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—meningioma	0.000215	0.000346	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—meningioma	0.000211	0.000339	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—meningioma	0.000201	0.000324	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.000198	0.000319	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—meningioma	0.000197	0.000318	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—meningioma	0.000192	0.000309	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—meningioma	0.000192	0.000309	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—meningioma	0.00019	0.000305	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TSHB—meningioma	0.000187	0.000302	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PDGFB—meningioma	0.000185	0.000298	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—meningioma	0.000185	0.000298	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—meningioma	0.000184	0.000295	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.00018	0.000289	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—meningioma	0.000177	0.000286	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—meningioma	0.000165	0.000266	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000165	0.000265	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000164	0.000264	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—meningioma	0.000164	0.000264	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—meningioma	0.000162	0.000261	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—meningioma	0.000156	0.000251	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—meningioma	0.000151	0.000243	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TSHB—meningioma	0.000145	0.000233	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—meningioma	0.00014	0.000225	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—meningioma	0.000139	0.000224	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—meningioma	0.000135	0.000217	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—meningioma	0.00013	0.000209	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—meningioma	0.000124	0.0002	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—meningioma	0.000123	0.000198	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—meningioma	0.000118	0.00019	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.000115	0.000184	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—meningioma	0.000114	0.000183	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—meningioma	0.000111	0.000178	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—meningioma	0.000106	0.00017	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—meningioma	0.000104	0.000167	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—meningioma	0.000103	0.000166	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—meningioma	9.44e-05	0.000152	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—meningioma	8.72e-05	0.00014	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—meningioma	8.47e-05	0.000136	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—meningioma	8.03e-05	0.000129	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—meningioma	8.01e-05	0.000129	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—meningioma	7.49e-05	0.000121	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—meningioma	7.34e-05	0.000118	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—meningioma	7.3e-05	0.000117	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—meningioma	7.23e-05	0.000116	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—meningioma	6.82e-05	0.00011	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—meningioma	6.39e-05	0.000103	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—meningioma	6.11e-05	9.83e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—meningioma	6.03e-05	9.7e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—meningioma	5.11e-05	8.22e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—meningioma	4.88e-05	7.86e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—meningioma	4.61e-05	7.43e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—meningioma	4.23e-05	6.81e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—meningioma	4.21e-05	6.77e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—meningioma	3.94e-05	6.34e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—meningioma	3.69e-05	5.93e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—meningioma	3.47e-05	5.59e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—meningioma	2.94e-05	4.73e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—meningioma	2.27e-05	3.65e-05	CbGpPWpGaD
